Shares of Hims & Hers Health Inc. (HIMS), a telehealth company that offers various healthcare products and services, including weight-loss drugs, plummeted by 5.03% on Monday. This significant drop in the stock price can be attributed to the increasing competition and uncertainties surrounding the weight-loss drug market.
The weight-loss drug industry has been in the spotlight recently, with companies like Eli Lilly and Novo Nordisk competing for market share with their branded medications, Zepbound and Wegovy, respectively. However, the emergence of compounding pharmacies and telehealth platforms offering cheaper copycat versions of these drugs has posed a significant challenge to the major pharmaceutical companies.
As reported by Barron's, the Food and Drug Administration (FDA) is expected to make a crucial decision on Thursday regarding whether Eli Lilly's supply of Zepbound can meet the U.S. demand. If the FDA determines that Zepbound is not in shortage, it could potentially limit the availability of cheaper compounded versions, which have been gaining popularity among consumers seeking affordable weight-loss solutions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。